Toronto (September 20, 2017) — Borden Ladner Gervais (BLG) congratulates Anthony Giovinazzo on receiving the inaugural 2017 Bloom Burton Award, an award that will be presented annually to an individual scientist, inventor, executive, entrepreneur, industry leader or policy maker who had the greatest impact on Canada's innovative healthcare industry within the past year.

The award recognizes Mr. Giovinazzo's leadership of Cynapsus Therapeutics Inc. (Cynapsus) in negotiating and concluding [in October 2016] its US$635M acquisition by Sunovion Pharmaceuticals Inc., the largest life sciences transaction in Canada in the last five years. Mr. Giovinazzo was one of the three original inventors and patent holders of the Cynapsus Parkinson's focused technology. Mr. Giovinazzo was selected as the 2017 Bloom Burton Award recipient by a panel of judges that included international leaders in healthcare investment, entrepreneurship and journalism.

BLG has worked closely with Mr. Giovinazzo over the course of his highly successful career as a leading executive within the life science sector in Canada, including acting as lead Canadian counsel to Cynapsus. BLG's Life Sciences Group is one of the largest in Canada, with considerable experience in intellectual property, financing, commercialization, licensing, regulatory compliance, advocacy and dispute resolution.

About Borden Ladner Gervais LLP

Borden Ladner Gervais LLP (BLG) is a leading, national, full-service Canadian law firm focusing on business law, commercial litigation and arbitration, and intellectual property solutions for our clients. BLG is one of the country’s largest law firms with more than 700 lawyers, intellectual property agents and other professionals in five cities across Canada. We assist clients with their legal needs, from major litigation to financing to trademark and patent registration.

For more information, please contact:

Tia Thomas
Environics Communications